SIRIUSPOINT LTD. (SPNT): what the price assumes

In the published model solve dated 2026-Q2, anchored at $23.61, SIRIUSPOINT LTD. (SPNT) is priced for 10.0% return on equity. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-11.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/SPNT

Headline

FieldValue
TickerSPNT
CompanySIRIUSPOINT LTD.
Sector / IndustryFinancial Services
Current price$23.61/sh
CompositionInsurance & Services 57% / Reinsurance 43%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Return on equity needed10.0%
Return on equity now18.0%
ROE gap-8.0pp
Price-to-book1.21x

Solve inputs: computed at a 9% cost of equity with 4% terminal growth over a 10-year stage, on common book equity (FY2026); each 1pp of cost of equity moves the implied ROE ~1.2pp.

How unusual the bet is: within-range

ReferenceValue
vs own history+0.49σ
cohort percentile (of 88 peers)23
sustained it ~10 years at this level76%
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset0.50x3justifies
Earnings0.54x1justifies
Relative0
Growth0

Families that justify the price: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.9%); the inversion above states its own rate.

Per-Model Detail (n=4)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowthno
Bank Fair Value (P/TBV)$73.920.32xyesTBVPS $18.25 × 4.05x (ROE (TTM) 22.2% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption))
Relative ValuationRelativenoP/E 8.77x (blended: static sector reference 11x + trailing (TTM) 5x), scenarios: 7.1x / 8.8x / 10.4x (bear / base = reference held flat / bull), EV/EBITDA 10x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$47.050.50xyesBV/sh $19.59, ROE (TTM) 22.2%, ke 9.3%
Two-Stage Excess ReturnAsset$72.560.33xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowthnoRev $3.2B, growth 25% (input: historical growth; tapered), Terminal P/S: 0.7x / 0.8x / 1.0x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelativenoEPS $4.05, growth 2% (input: historical EPS growth), PEG=2.71 (Overvalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarningsno
Residual IncomeAssetno
Graham NumberAsset$42.250.56xyes√(22.5 × EPS $4.05 × BVPS $19.59) — Graham's conservative floor
EV/EBITDA RelativeRelativeno
FCF YieldEarningsno
SBC-Adj FCF YieldEarningsno
Ben Graham FormulaEarningsnoEPS $4.05 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAssetno
P/Sales SectorRelativeno
PEG Fair ValueRelativenoEPS $4.05 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$43.780.54xyesEPS $4.05 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Economic-Unit Decomposition (Sum Of The Parts)

The issuer is a funded financial business. Debt, interest, and cash flows are operating inputs, so industrial EV, net-debt, WACC, and free-cash-flow lenses do not apply; value the common-equity claim with book, earnings, capital, and payout economics.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Insurance & Servicesfinancialequity$1.5bwithheldunresolved standalone equity facts required
Reinsurancefinancialequity$1.1bwithheldunresolved standalone equity facts required

No unit-level total common-equity value is stated. Each financial unit requires supported standalone common equity, normalized earnings, capital adequacy, and payout capacity. Consolidated debt, interest, and cash are operating balances, not an enterprise-to-equity bridge; company-level book, earnings, capital, and payout lenses remain the coherent cross-checks.

Solvency

FieldValue
Share count CAGR (buyback)-7.2%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Bull Case

Read SiriusPoint as a company that has changed stage, because the numbers only make sense that way. The turnaround years, portfolio pruning, reserve cleanup, and preference-share redemption, are functionally over, and the metrics coming out the other side are those of a compounding specialty underwriter: first-quarter net income of $100 million, return on equity of 17.4% for the quarter, operating EPS up 37% to $0.70, and a consolidated combined ratio of 87.8%, meaning the insurance operations make almost twelve cents of underwriting profit per premium dollar before a dime of investment income. Three rating agencies re-graded the story in real time, upgrading financial strength to A, which is not a lagging cosmetic: an A rating lowers the cost of doing business and widens the set of clients a specialty carrier can write.

The model is distribution-led and deliberately picky. SiriusPoint "is a carrier for program administrators and MGAs" [FY2025 10-K, accession 0001576018-26-000032], growing Insurance & Services premium 8% while shrinking Reinsurance premium 10% where pricing no longer clears its return bar. That is what underwriting discipline looks like in the data: growth where the margins are, retreat where they are not. Recent reserve history supports the quality claim, with 2025 showing $73.8 million of net favorable prior-year development, including $32.1 million in Insurance & Services [FY2025 10-K, accession 0001576018-26-000032]; conservative reserving that releases over time is the signature of an underwriting culture that earns its combined ratio honestly.

Capital allocation is doing the compounding arithmetic. Over $240 million went back to holders around the first quarter, including the $200 million preference-share redemption and $40 million-plus of common repurchases, with the buyback commitment expanded to the full $174 million authorization; the share count is already down about 6.6% a year over four years. The price, meanwhile, asks very little: at roughly 1.3 times book, the market is paying for a sustained return on equity around 10%, roughly half what the business is earning now. A specialty insurer earning high-teens returns, upgraded to A, shrinking its own share count, and priced in the lower half of its peer group's price-to-book is a bet where the requirement sits far below the demonstrated.

Bear Case

One external variable runs this thesis: the property-casualty pricing cycle, and it is turning. SiriusPoint's own premium decisions say so; management is shrinking reinsurance 10% and warning it will only write "risks that offer adequate returns" in property catastrophe and selected casualty, which is what a carrier does when the market softens and competitors underprice risk. The high-teens returns on equity the company earns today were built in the hardest reinsurance pricing market in a generation; a soft market grinds that toward the priced-in 10% not through any company failure, but through the industry-wide arithmetic of more capital chasing the same premium. The base rate in the input is blunt about persistence: only about 75% of firms earning returns at this level sustained them for a decade, and that is the favorable reading, since it counts survivors of ordinary cycles, not carriers that leaned into MGA-sourced program business late in a cycle.

The balance-sheet risk is reserve risk, and the 10-K names it with unusual candor: reserves tied to recent large catastrophe events "remain subject to meaningful uncertainty, and as information emerges and claims develop, we expect our reserves may change, perhaps materially", with the filing adding "we may underestimate the exposures we are" carrying [FY2025 10-K, accession 0001576018-26-000032]. At 1.3 times book, every dollar of adverse development destroys $1.30 of market value mechanically before sentiment does anything. The program-and-MGA distribution model compounds this: a carrier fronting for program administrators inherits the underwriting of partners whose incentives are commission-driven, and problems in program business surface with a lag measured in years, not quarters.

Timing adds its own tax. The 2026 growth guide of 5 to 10% is explicitly weighted to the second half, so the next print or two carry soft top-line optics while the buyback spends capital at a price already re-rated well off the turnaround lows. The quarter that produced the 87.8% combined ratio also benefited from lower catastrophe losses; hurricane seasons are not evenly distributed, and a normal-cat second half against softening pricing would show what the underlying engine earns without weather luck. The market pricing this at a discount to every standard lens is not asleep; it is charging for cycle, reserves, and the memory of what this company was before the turnaround.

Valuation

An insurer is priced on the return it earns on its capital, so start at price-to-book: at $24.65 the market pays about 1.3 times book, which at a 9% cost of equity implies a sustained return on equity of roughly 10.3%. The company has recently been earning about 18%, and the first quarter ran at 17.4% (15.3% on the operating measure). The requirement is within reach of the record, the multiple sits in the lower half of the peer group's price-to-book, and about 75% of firms earning returns at this level sustained them for ten years. As priced-in bets go, this one is set below the demonstrated run rate, which is the analytical headline of the whole report.

The triangulating lenses agree with unusual unanimity: every family lands above today's price. Book-value-based arithmetic reads the price at roughly half its central estimate, earnings-based reads sit further above, peer multiples land about double the price, and even the forward-growth lens, typically the most demanding, sits about 20% above. When all four families clear the price, the market is not disputing the numbers; it is discounting their durability, for cycle and reserve reasons, and pricing SiriusPoint below where its current economics would place a carrier it fully trusted.

The solvency read for an insurer is capital and payout capacity, not corporate leverage; debt on a float-funded balance sheet is funding, not borrowings against earnings. On that frame: financial-strength ratings were upgraded to A across S&P, Fitch, and AM Best; the company redeemed the entire $200 million of preference shares, simplifying the capital stack; returned over $240 million in the recent period; and committed to the full $174 million buyback authorization for 2026. The share count has compounded down 6.6% a year for four years. Reserve development is the swing item under the book value everything is priced against: 2025 delivered $73.8 million of net favorable development [FY2025 10-K, accession 0001576018-26-000032], and each future quarter's development line either validates the 1.3 times book or reprices it.

Catalysts

The May 7 first-quarter report is the reference print: net income of $100 million, quarterly return on equity of 17.4%, operating EPS of $0.70 (up 37%), a consolidated combined ratio of 87.8%, and a Core combined ratio of 88.9%, the best in six quarters, on lower catastrophe losses and improved underlying underwriting. Insurance & Services grew gross written premium 8% while Reinsurance shrank 10% on pricing discipline. The next quarterly print tests whether the sub-90 combined ratio survives a quarter with ordinary catastrophe weather.

Three structural catalysts are live. First, the ratings reset: A-grade financial strength from S&P, Fitch, and AM Best typically expands business eligibility over subsequent quarters, so watch new program and specialty wins. Second, capital returns: the buyback commitment was raised by $74 million to the full $174 million authorization, following the $200 million preference redemption; execution pace shows up directly in the share count. Third, the 2026 growth guide of 5 to 10% gross written premium, explicitly second-half-weighted as the book rebalances toward insurance and London Market specialty; a first half that undershoots on optics is by design, and the market's patience with that cadence is itself the trade.

The macro variable to track between prints is reinsurance pricing at the mid-year renewals; management has said it will shift capital or reduce exposure where pricing does not match risk, so renewal commentary doubles as a leading indicator of both discipline and top-line trajectory.

Peer Cohorts (Per Segment, With Filing Citations)

Insurance & Services (reported)

Reinsurance (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q1 2026 earnings release, May 7, 2026 · Q1 2026 earnings call, 2026 · Q1 2026 earnings release and Seeking Alpha, May 2026 · Q1 2026 earnings release and call, May 2026 · Seeking Alpha, May 2026

View the full interactive SPNT report on boothcheck